(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 4.45% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.23%.
Bioventus's revenue in 2024 is $512,345,000.On average, 1 Wall Street analysts forecast BVS's revenue for 2024 to be $41,884,903,903, with the lowest BVS revenue forecast at $41,884,903,903, and the highest BVS revenue forecast at $41,884,903,903. On average, 1 Wall Street analysts forecast BVS's revenue for 2025 to be $44,277,286,522, with the lowest BVS revenue forecast at $44,277,286,522, and the highest BVS revenue forecast at $44,277,286,522.
In 2026, BVS is forecast to generate $46,578,628,770 in revenue, with the lowest revenue forecast at $46,578,628,770 and the highest revenue forecast at $46,578,628,770.